A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Latest Information Update: 02 Aug 2024
At a glance
- Drugs BGB-15025 (Primary) ; Tislelizumab (Primary)
- Indications Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors BeiGene
- 04 Jun 2024 Results (n= 109, data cut-off: 21 Nov 2023), assessing dose-escalation of BGB-15025 as monotherapy and in combination with tislelizumab, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 07 May 2024 Planned End Date changed from 1 Aug 2024 to 1 Mar 2025.
- 07 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.